Document 0559
 DOCN  M9440559
 TI    Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
 DT    9404
 AU    Money-Kyrle JF; Bates F; Ready J; Gazzard BG; Phillips RH; Boag FC;
       Kobler Centre, St Stephen's Clinic, London, UK.
 SO    Clin Oncol (R Coll Radiol). 1993;5(6):367-71. Unique Identifier :
       AIDSLINE MED/94137635
 AB    We report a non-randomized Phase II clinical trial to assess the
       efficacy and safety of liposomal daunorubicin (DaunoXome) in the
       treatment of AIDS related Kaposi's sarcoma. Eleven homosexual men with
       advanced Kaposi's sarcoma were entered in the trial. Changes in size,
       colour and associated oedema of selected 'target' lesions were measured.
       Clinical, biochemical and haematological toxicities were assessed. Ten
       subjects were evaluated. A partial response was achieved in four, of
       whom two subsequently relapsed. Stabilization of Kaposi's sarcoma
       occurred in the remaining six, maintained until the end of the trial
       period in four. The drug was generally well tolerated, with few mild
       symptoms of toxicity. The main problem encountered was haematological
       toxicity, with three subjects experiencing severe neutropenia
       (neutrophil count < 0.5 x 10(9)/l). There was no evidence of
       cardiotoxicity. In this small patient sample, liposomal daunorubicin was
       an effective and well tolerated agent in the treatment of Kaposi's
       sarcoma.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Adult
       Anemia/CHEMICALLY INDUCED  Daunorubicin/*ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS  Drug Carriers  Human  Liposomes  Male  Middle Age
       Neutropenia/CHEMICALLY INDUCED  Recurrence  Sarcoma, Kaposi's/*DRUG
       THERAPY/ETIOLOGY  Treatment Outcome  CLINICAL TRIAL  CLINICAL TRIAL,
       PHASE II  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).